Discovery - University of Dundee - Online Publications

Library & Learning Centre

The importance of nonpharmacogenetic factors in endocrine therapy

Standard

The importance of nonpharmacogenetic factors in endocrine therapy. / McCowan, Colin; Thompson, Alastair M.

In: Pharmacogenomics, Vol. 13, No. 6, 04.2012, p. 721-728.

Research output: Contribution to journalLiterature review

Harvard

McCowan, C & Thompson, AM 2012, 'The importance of nonpharmacogenetic factors in endocrine therapy' Pharmacogenomics, vol 13, no. 6, pp. 721-728. DOI: 10.2217/PGS.12.29

APA

McCowan, C., & Thompson, A. M. (2012). The importance of nonpharmacogenetic factors in endocrine therapy. Pharmacogenomics, 13(6), 721-728. DOI: 10.2217/PGS.12.29

Vancouver

McCowan C, Thompson AM. The importance of nonpharmacogenetic factors in endocrine therapy. Pharmacogenomics. 2012 Apr;13(6):721-728. Available from, DOI: 10.2217/PGS.12.29

Author

McCowan, Colin; Thompson, Alastair M. / The importance of nonpharmacogenetic factors in endocrine therapy.

In: Pharmacogenomics, Vol. 13, No. 6, 04.2012, p. 721-728.

Research output: Contribution to journalLiterature review

Bibtex - Download

@article{8b8f910276e942cba262c8cf6616af06,
title = "The importance of nonpharmacogenetic factors in endocrine therapy",
author = "Colin McCowan and Thompson, {Alastair M.}",
year = "2012",
month = "4",
doi = "10.2217/PGS.12.29",
volume = "13",
pages = "721--728",
journal = "Pharmacogenomics",
issn = "1462-2416",
number = "6",

}

RIS (suitable for import to EndNote) - Download

TY - JOUR

T1 - The importance of nonpharmacogenetic factors in endocrine therapy

AU - McCowan,Colin

AU - Thompson,Alastair M.

PY - 2012/4

Y1 - 2012/4

N2 - <p>Nonpharmacogenetic factors may play a key role in the success of oral endocrine therapy for breast cancer. Adherence, defined as following medical advice as well as persistence and duration of use for patients prescribed endocrine therapy, may impact significantly on recurrence and survival. Side effects from tamoxifen or aromatase inhibitors may lead to patients stopping or switching therapy, while comorbidities, consequent coprescribing and patient perceptions may also influence outcomes. Interventions to improve adherence and persistence are required and could have as great an effect on survival as applying pharmacogenetic principles to the endocrine management of breast cancer.</p>

AB - <p>Nonpharmacogenetic factors may play a key role in the success of oral endocrine therapy for breast cancer. Adherence, defined as following medical advice as well as persistence and duration of use for patients prescribed endocrine therapy, may impact significantly on recurrence and survival. Side effects from tamoxifen or aromatase inhibitors may lead to patients stopping or switching therapy, while comorbidities, consequent coprescribing and patient perceptions may also influence outcomes. Interventions to improve adherence and persistence are required and could have as great an effect on survival as applying pharmacogenetic principles to the endocrine management of breast cancer.</p>

U2 - 10.2217/PGS.12.29

DO - 10.2217/PGS.12.29

M3 - Literature review

VL - 13

SP - 721

EP - 728

JO - Pharmacogenomics

T2 - Pharmacogenomics

JF - Pharmacogenomics

SN - 1462-2416

IS - 6

ER -

Documents

DOI

Library & Learning Centre

Contact | Accessibility | Policy